172 related articles for article (PubMed ID: 29736307)
1. A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models.
Wang R; Lai Q; Tang L; Tao Y; Yao Y; Liu Y; Lu Y; Shen C; Lu R; Fan C; Zhang R; Wang Y; Yu L; Yang T; Wu Y; Peng Y; Wei X; Fu Y; Lai W; Gou L; Yang J
Am J Cancer Res; 2018; 8(4):610-623. PubMed ID: 29736307
[TBL] [Abstract][Full Text] [Related]
2. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.
Tao Y; Wang R; Lai Q; Wu M; Wang Y; Jiang X; Zeng L; Zhou S; Li Z; Yang T; Yao Y; Wu Y; Yu L; Fu Y; Lai W; Peng Y; Lu Y; Zhang Z; Guo C; Zhang G; Gou L; Yang J
Mol Oncol; 2019 Sep; 13(9):1855-1873. PubMed ID: 31116512
[TBL] [Abstract][Full Text] [Related]
3. ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
Smith RA; Zammit DJ; Damle NK; Usansky H; Reddy SP; Lin JH; Mistry M; Rao NS; Denis LJ; Gupta S
Mol Cancer Ther; 2021 Aug; 20(8):1327-1337. PubMed ID: 34045226
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
5. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
6. DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis.
Wu Y; Li W; Chen X; Wang H; Su S; Xu Y; Deng X; Yang T; Wei M; Li L; Liu Y; Yang J; Li W
Front Immunol; 2023; 14():1051506. PubMed ID: 36776873
[TBL] [Abstract][Full Text] [Related]
7. Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
Schunselaar LM; Monkhorst K; van der Noort V; Wijdeven R; Peters D; Zwart W; Neefjes J; Baas P
J Thorac Oncol; 2018 Oct; 13(10):1577-1587. PubMed ID: 29959059
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography.
Giddabasappa A; Gupta VR; Norberg R; Gupta P; Spilker ME; Wentland J; Rago B; Eswaraka J; Leal M; Sapra P
Mol Cancer Ther; 2016 Oct; 15(10):2530-2540. PubMed ID: 27466353
[TBL] [Abstract][Full Text] [Related]
10. Expression of 5T4 extracellular domain fusion protein and preparation of anti-5T4 monoclonal antibody with high affinity and internalization efficiency.
Wang R; Lai Q; Lu Y; Zhou Y; Tang L; Tao Y; Yao Y; Yu L; Liu Y; Wang Y; Zhang R; Jiang X; Gou L; Yang J
Protein Expr Purif; 2019 Jun; 158():51-58. PubMed ID: 29981846
[TBL] [Abstract][Full Text] [Related]
11. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
Boghaert ER; Sridharan L; Khandke KM; Armellino D; Ryan MG; Myers K; Harrop R; Kunz A; Hamann PR; Marquette K; Dougher M; DiJoseph JF; Damle NK
Int J Oncol; 2008 Jan; 32(1):221-34. PubMed ID: 18097562
[TBL] [Abstract][Full Text] [Related]
12. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
13. Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.
McGinn OJ; Krishnan S; Bourquin JP; Sapra P; Dempsey C; Saha V; Stern PL
Haematologica; 2017 Jun; 102(6):1075-1084. PubMed ID: 28341731
[TBL] [Abstract][Full Text] [Related]
14. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.
Sapra P; Damelin M; Dijoseph J; Marquette K; Geles KG; Golas J; Dougher M; Narayanan B; Giannakou A; Khandke K; Dushin R; Ernstoff E; Lucas J; Leal M; Hu G; O'Donnell CJ; Tchistiakova L; Abraham RT; Gerber HP
Mol Cancer Ther; 2013 Jan; 12(1):38-47. PubMed ID: 23223830
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer.
Wan YL; Sapra P; Bolton J; Chua JX; Durrant LG; Stern PL
Target Oncol; 2019 Aug; 14(4):465-477. PubMed ID: 31332693
[TBL] [Abstract][Full Text] [Related]
16. Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.
Nguyen TD; Bordeau BM; Balthasar JP
Mol Cancer Ther; 2023 Nov; 22(11):1332-1342. PubMed ID: 37493255
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
18. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
[TBL] [Abstract][Full Text] [Related]
20. Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
Pouzin C; Gibiansky L; Fagniez N; Chadjaa M; Tod M; Nguyen L
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):381-394. PubMed ID: 35166967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
